413 related articles for article (PubMed ID: 31344332)
21. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
[TBL] [Abstract][Full Text] [Related]
22. [Up to date lipid lowering treatment].
Paragh G; Karádi I
Orv Hetil; 2016 Jul; 157(31):1219-23. PubMed ID: 27476517
[TBL] [Abstract][Full Text] [Related]
23. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM
Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356
[TBL] [Abstract][Full Text] [Related]
24. Anti-Inflammatory Effects of Lipid-Lowering Drugs and Supplements-A Narrative Review.
Zivkovic S; Maric G; Cvetinovic N; Lepojevic-Stefanovic D; Bozic Cvijan B
Nutrients; 2023 Mar; 15(6):. PubMed ID: 36986246
[TBL] [Abstract][Full Text] [Related]
25. Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events.
O'Keefe JH; DiNicolantonio JJ; Lavie CJ
Am J Cardiol; 2017 Feb; 119(4):565-571. PubMed ID: 28081940
[TBL] [Abstract][Full Text] [Related]
26. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
[TBL] [Abstract][Full Text] [Related]
27. LDL-cholesterol lowering and renal outcomes.
Waters DD
Curr Opin Lipidol; 2015 Jun; 26(3):195-9. PubMed ID: 25887677
[TBL] [Abstract][Full Text] [Related]
28. Lipid-lowering treatment in peripheral artery disease.
Katsiki N; Giannoukas AD; Athyros VG; Mikhailidis DP
Curr Opin Pharmacol; 2018 Apr; 39():19-26. PubMed ID: 29413998
[TBL] [Abstract][Full Text] [Related]
29. Detection of atherosclerotic cardiovascular disease influences the perceived need for aggressive lipid management.
Mancini GBJ; Gupta M; Tsigoulis M; Cannon CP; Genest J; Ray KK; Santos RD; Watts GF; Raggi P
Atherosclerosis; 2017 Aug; 263():112-118. PubMed ID: 28623740
[TBL] [Abstract][Full Text] [Related]
30. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials.
Koskinas KC; Siontis GCM; Piccolo R; Mavridis D; Räber L; Mach F; Windecker S
Eur Heart J; 2018 Apr; 39(14):1172-1180. PubMed ID: 29069377
[TBL] [Abstract][Full Text] [Related]
31. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
[TBL] [Abstract][Full Text] [Related]
32. Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease.
Mathew RO; Rosenson RS; Lyubarova R; Chaudhry R; Costa SP; Bangalore S; Sidhu MS
Cardiovasc Drugs Ther; 2021 Jun; 35(3):479-489. PubMed ID: 32556851
[TBL] [Abstract][Full Text] [Related]
33. Clinical characteristics and lipid lowering treatment of patients initiated on proprotein convertase subtilisin-kexin type 9 inhibitors: a nationwide cohort study.
Jensen JS; Weeke PE; Bang LE; Høfsten DE; Ripa MS; Schjerning AM; Theilade JE; Køber LV; Gislason GH; Pallisgaard J
BMJ Open; 2019 Apr; 9(4):e022702. PubMed ID: 30940751
[TBL] [Abstract][Full Text] [Related]
34. Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9): Impact of PCSK9 on Major Adverse Cardiac and Cerebrovascular Events.
Akin M; Skripuletz T; Napp LC; Berliner D; Akin I; Haghikia A; Akin E; Bauersachs J
Cardiovasc Hematol Agents Med Chem; 2017; 14(2):94-100. PubMed ID: 27470008
[TBL] [Abstract][Full Text] [Related]
35. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients.
Costet P; Hoffmann MM; Cariou B; Guyomarc'h Delasalle B; Konrad T; Winkler K
Atherosclerosis; 2010 Sep; 212(1):246-51. PubMed ID: 20619837
[TBL] [Abstract][Full Text] [Related]
36. Impact of conventional lipid-lowering therapy on circulating levels of PCSK9: protocol for a systematic review and meta-analysis of randomised controlled trials.
Luo J; Huang T; Xu R; Wang X; Yang Y; Li L; Zhang X; Zhang Y; Yang R; Wang J; Yang H; Ma Y; Yang B; Wang T; Jiao L
BMJ Open; 2022 Sep; 12(9):e061884. PubMed ID: 36691198
[TBL] [Abstract][Full Text] [Related]
37. [Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant].
Karie S; Launay-Vacher V; Deray G; Isnard-Bagnis C
Presse Med; 2006 Feb; 35(2 Pt 1):219-29. PubMed ID: 16493350
[TBL] [Abstract][Full Text] [Related]
38. Endothelin Receptor Antagonism Improves Lipid Profiles and Lowers PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) in Patients With Chronic Kidney Disease.
Farrah TE; Anand A; Gallacher PJ; Kimmitt R; Carter E; Dear JW; Mills NL; Webb DJ; Dhaun N
Hypertension; 2019 Aug; 74(2):323-330. PubMed ID: 31177906
[TBL] [Abstract][Full Text] [Related]
39. A Systematic Review of Cost-Effectiveness of Non-Statin Lipid-Lowering Drugs for Primary and Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus.
Abushanab D; Al-Badriyeh D; Marquina C; Bailey C; Jaam M; Liew D; Ademi Z
Curr Probl Cardiol; 2023 Aug; 48(8):101211. PubMed ID: 35460688
[TBL] [Abstract][Full Text] [Related]
40. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?
Cervelli N; Tocci G; Ferri C
High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
